Discovery is major step towards a stem cell replacement therapy for Duchenne Muscular Dystrophy
UCLA scientists have developed a new strategy to efficiently isolate, mature and transplant skeletal muscle cells created from human pluripotent stem cells, which can produce all cell types of the body. The findings are a major step towards developing a stem cell replacement therapy for muscle diseases including Duchenne Muscular Dystrophy, which affects approximately 1 in 5,000 boys in the U.S. and is the most common fatal childhood genetic disease.
The study was published in the journal Nature Cell Biology by senior author April Pyle, associate professor of microbiology, immunology and molecular genetics and member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. Using the natural human development process as a guide, the researchers developed ways to mature muscle cells in the laboratory to create muscle fibers that restore dystrophin, the protein that is missing in the muscles of boys with Duchenne.
Without dystrophin, muscles degenerate and become progressively weaker. Duchenne symptoms usually begin in early childhood; patients gradually lose mobility and typically die from heart or respiratory failure around age 20. There is currently no way to reverse or cure the disease.
For years, scientists have been trying different methods that direct human pluripotent stem cells to generate skeletal muscle stem cells that can function appropriately in living muscle and regenerate dystrophin-producing muscle fibers. However, the study led by Pyle found that the current methods are inefficient; they produce immature cells that are not appropriate for modeling Duchenne in the laboratory or creating a cell replacement therapy for the disease.
“We have found that just because a skeletal muscle cell produced in the lab expresses muscle markers, doesn’t mean it is fully functional,” said Pyle. “For a stem cell therapy for Duchenne to move forward, we must have a better understanding of the cells we are generating from human pluripotent stem cells compared to the muscle stem cells found naturally in the human body and during the development process.”
By analyzing human development, the researchers found a fetal skeletal muscle cell that is extraordinarily regenerative. Upon further analysis of these fetal muscle cells two new cell surface markers called ERBB3 and NGFR were discovered; this enabled the reserchers to precisely isolate muscle cells from human tissue and separate them from various cell types created using human pluripotent stem cells.
Once they were able to isolate skeletal muscle cells using the newly identified surface markers, the research team matured those cells in the lab to create dystrophin-producing muscle fibers. The muscle fibers they created were uniformily muscle cells, but the fibers were still smaller than those found in real human muscle.
“We were missing another key component,” said Michael Hicks, lead author of the study. The skeletal muscle cells were not maturing properly, he explained. “We needed bigger, stronger muscle that also had the ability to contract.”
Once again, the team looked to the natural stages of human development for answers. Hicks discovered that a specific cell signaling pathway called TGF Beta needs to be turned off to enable generation of skeletal muscle fibers that contain the proteins that help muscles contract. Finally, the team tested their new method in a mouse model of Duchenne.
“Our long term goal is to develop a personalized cell replacement therapy using a patient’s own cells to treat boys with Duchenne,” said Hicks. “So, for this study we followed the same steps, from start to finish, that we’d follow when creating these cells for a human patient.”
First, the Duchenne patient cells were reprogrammed to become pluripotent stem cells. The researchers then removed the genetic mutation that causes Duchenne using the gene editing technology CRISPR-Cas9. Using the ERBB3 and NGFR surface markers, the skeletal muscle cells were isolated and then injected into mice at the same time a TGF Beta inhibitor was administered.
“The results were exactly what we’d hoped for,” said Pyle. “This is the first study to demonstrate that functional muscle cells can be created in a laboratory and restore dystrophin in animal models of Duchenne using the human development process as a guide.”
Further research will focus on generating skeletal muscle stem cells that can respond to continuous injury and regenerate new muscle long-term using the team’s new isolation and maturation strategy.
Learn more: UCLA researchers create skeletal muscle from stem cells
The Latest on: Duchenne Muscular Dystrophy
[google_news title=”” keyword=”Duchenne Muscular Dystrophy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- Sarepta Elevidys accelerated approval criticized by ICER execon May 2, 2024 at 12:36 pm
The US FDA's accelerated approval process faces criticism over the approval of Sarepta Therapeutics' Duchenne muscular dystrophy treatment, Elevidys. Read more here.
- New type of muscular dystrophy discovered after girl’s diagnosison April 30, 2024 at 12:14 pm
An new type of muscular dystrophy that's caused by inherited mutations in the SNUPN gene results in symptoms of muscle weakness before age 2.
- Virtual Reality and Biofeedback Training Appear Effective for DMD, BMD Rehabilitationon April 29, 2024 at 11:57 am
A recent study suggests virtual reality and biofeedback training may be feasible and effective for patients with Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD).
- Parent Project Muscular Dystrophy Awards $250,000 to Support Clinical Research Network for Duchenne Babies Identified by Newborn Screeningon April 29, 2024 at 6:59 am
Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), is excited to announce a $250,000 award to Bo Hoon Lee, MD, from the ...
- Duchenne Muscular Dystrophy: the global clinical trials landscape 2024on April 29, 2024 at 4:02 am
Affecting muscle and skeletal strength, this rare genetic disorder impacts thousands of men worldwide. Innovative new genetic therapies in development across the globe are improving the quality of ...
- Patients With DMD Receiving Eteplirsen Show Prolonged Survival, Study Findson April 25, 2024 at 2:03 pm
The study provides evidence of survival benefits among patients with Duchenne muscular dystrophy (DMD) receiving eteplirsen compared with the natural history of the condition.
- DeWine: Ohio first state in the nation to screen newborn babies for Duchenne Muscular Dystrophyon April 24, 2024 at 9:00 pm
Ohio Gov. Mike DeWine on Monday announced that Ohio will become the first state in the nation to begin screening all newborn babies for Duchenne Muscular Dystrophy. The provision was included in HR 33 ...
- Ohio sets the trend in screening newborns for rare disease. What to know about DMDon April 24, 2024 at 3:58 am
Ohio Gov. Mike DeWine announced the state will be the first in the nation to screen newborns for the rare disease Duchenne Muscular Dystrophy.
- Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophyon April 24, 2024 at 1:59 am
Manufacturing and Controls (“CMC”) meeting with the U.S. Food and Drug Administration (“FDA”) on next steps for the Biologics License Application (“BLA”) submission with its lead asset CAP-1002 in ...
- My son's smile gives me hope for Duchenne muscular dystrophy. A new law could help otherson April 23, 2024 at 5:01 am
Opinion: Newborn testing can give families a head start on giving a child with the degenerative muscular disease a shot at the best outcome in life.
via Google News and Bing News